Prolonged haematologic toxicity in CAR‐T‐cell therapy: A review

Chimeric antigen receptor‐T‐cell (CAR‐T‐cell) therapy is a novel immunotherapy with encouraging results for treatment of relapsed/refractory haematologic malignancies. With increasing use, our understanding of immune‐mediated side effects such as cytokine release syndrome and neurotoxicity has impro...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular and molecular medicine 2023-12, Vol.27 (23), p.3662-3671
Main Authors: Liu, Qi, Hu, Tonglin, Li, Hangchao, Shen, Yingying, Wu, Dijiong, Ye, Baodong
Format: Article
Language:English
Subjects:
Anemia
Antigens
Blood platelets
Bone marrow
CAR‐T‐cell therapy
Cell therapy
Cell- and Tissue-Based Therapy
Chemotherapy
Chimeric antigen receptors
Cytokines
Growth factors
Hematologic Neoplasms - therapy
Hemoglobin
Humans
Immunotherapy
Immunotherapy, Adoptive - adverse effects
Immunotherapy, Adoptive - methods
Lymphocytes
Lymphocytes T
Malignancy
management
mechanism
Neoplasm Recurrence, Local - drug therapy
Neurotoxicity
Neutropenia
Neutrophils
Oncology
Patients
prolonged haematologic toxicity
Proteins
Receptors, Chimeric Antigen - genetics
Review
Reviews
Risk factors
Stem cells
Thrombocytopenia
Toxicity
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chimeric antigen receptor‐T‐cell (CAR‐T‐cell) therapy is a novel immunotherapy with encouraging results for treatment of relapsed/refractory haematologic malignancies. With increasing use, our understanding of immune‐mediated side effects such as cytokine release syndrome and neurotoxicity has improved; nevertheless, prolonged haematologic toxicity (PHT), with a high incidence rate, remains underrecognized. Owing to heterogeneity in populations, the CAR‐T cells used and diseases treated as well as differences in the definition of PHT, its rate, risk factors and management vary across studies. In this review, we provide a narrative of PHT occurring in patients following CAR‐T‐cell therapy; evidence of PHT treatment strategies is also presented, with the aim of contributing to systematic understanding of PHT.
ISSN:1582-1838
1582-4934
DOI:10.1111/jcmm.17930